
Loading, please wait...

Loading, please wait...

Spinal cord injury (SCI) often leads to permanent disability because of a secondary damage cascade. However, a recent study introduces a combined blood glutamate scavenging SCI platform that provides robust neuroprotection. This first-in-class therapy targets glutamate excitotoxicity, which is a primary driver of neuronal death after trauma.
Glutamate levels rise sharply after an injury to the spinal cord. Therefore, this excess glutamate overstimulates receptors, which triggers a cycle of cell death. The cBGS platform uses recombinant enzymes like rGOT1 and rGPT1 to lower blood glutamate levels. Consequently, this creates a concentration gradient that draws toxic glutamate out of the central nervous system. This process of blood glutamate scavenging SCI effectively halts the destructive secondary injury process.
Furthermore, researchers tested the platform in various rodent models of spinal cord compression. The results showed that systemic administration significantly reduced glutamate in both the blood and cerebrospinal fluid. Notably, animals treated with cBGS exhibited up to 80% improvement in locomotor performance. Moreover, the treatment remained effective even when researchers administered it eight hours after the initial trauma. Because of this wide therapeutic window, the therapy is highly promising for clinical use in emergency settings. In addition, an external laboratory independently validated these findings, confirming the safety and efficacy of the platform.
By lowering glutamate levels in the blood, the therapy creates a gradient that pulls toxic excess glutamate out of the spinal cord, preventing further nerve damage.
While most neuroprotective drugs have very short windows, this cBGS platform showed efficacy up to eight hours post-injury in animal models.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or to replace the expertise of a qualified healthcare professional. Refer to the latest local and national guidelines for clinical practice.
References
1. Levin J et al. Breaking the cycle of excitotoxicity: blood glutamate scavenging provides robust neuroprotection in spinal cord injury. Inflamm Regen. 2026 Feb 27. doi: 10.1186/s41232-026-00411-x. PMID: 41749407.
2. Ruban L et al. Blood Glutamate Scavenger as a Novel Neuroprotective Treatment in Spinal Cord Injury. J Neurotrauma. 2018 Nov 1;35(21):2581-2590. doi: 10.1089/neu.2017.5524.
3. Boyko M et al. Brain to blood glutamate scavenging as a novel therapeutic modality: A review. J Neural Transm (Vienna). 2014 Aug;121(8):971-9. doi: 10.1007/s00702-014-1181-z.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A new enzymatic platform (cBGS) effectively scavenges blood glutamate to protect neurons and restore function after spinal cord injury in preclinical models...
7 months ago

A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today

Occult maternal malignancy accounts for 3.82% of persistent unreportable NIPT results with genomic noise. Multiple chromosomal aberrations, notably on chromosome 18, warrant thorough oncological evaluation and whole-body MRI to ensure timely maternal diagnosis while preserving fetal care.
Today

This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday